Under New Policy, FDA Will Cut Off ‘Interim’ Compounding Of Some New Drugs

By Jessica Karins / January 8, 2025 at 1:27 PM

FDA will limit the drug substances that can be compounded by 503A and 503B outsourcing facilities after being proposed for, but not yet approved for, its lists of bulk drug substances, the agency says in new guidance on the issue.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.